drugset
drugset / Trial / NCT05754996

Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis

NCT05754996 ↗

Phase 3 Completed 80 enrolled Cairo University
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a pilot study designed to evaluate the efficacy and safety of nifuroxazide in the treatment of hepatic encephalopathy in patients with grade II-III hepatic encephalopathy

Timeline

Start
2023-03-12
Primary completion
2025-07-29
Completion
2025-07-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Nifuroxazide Small molecule 200 mg Oral
Background Lactulose Other / unclassified 30 ml Oral
Background Lactulose Other / unclassified 60 ml Oral
Background Rifaximin Other / unclassified 550 mg —

Indications

hepatic encephalopathy